TransCode Therapeutics, Inc. (RNAZ) ownership: Top institutional holder: GOLDMAN SACHS GROUP INC ($218728.00). Insider activity: Net Seller (0 buys, 4 sells). SEC EDGAR first-party data.
| Holder | Shares | Market Value | Reported |
|---|---|---|---|
| GOLDMAN SACHS GROUP INC | 28042.00 | $218728.00 | 2025-06-30 |
| GEODE CAPITAL MANAGEMENT, LLC | 12740.00 | $109690.00 | 2026-03-31 |
| UBS Group AG | 8295.00 | $71420.00 | 2026-03-31 |
| VANGUARD CAPITAL MANAGEMENT LLC | 6545.00 | $56352.00 | 2026-03-31 |
| VANGUARD FIDUCIARY TRUST CO | 2982.00 | $25675.00 | 2026-03-31 |
| CITADEL ADVISORS LLC | 25512.00 | $25640.00 | 2024-06-30 |
| MORGAN STANLEY | 5000.00 | $2475.00 | 2025-03-31 |
| Tower Research Capital LLC (TRC) | 228.00 | $1963.00 | 2026-03-31 |
| Insider | Transaction | Value | Date |
|---|---|---|---|
| Sell | null | 2026-08-03 | |
| Sell | null | 2026-08-03 | |
| Sell | null | 2026-08-03 | |
| Sell | null | 2026-08-03 |
Back to RNAZ overview · RNAZ earnings · All congressional trades
Institutional data from SEC Form 13F. Insider data from SEC Form 4. Congressional data from STOCK Act disclosures. Not personalized investment advice.